Akero Therapeutics KUV 2025

Hva gjør Akero Therapeutics?

Akero Therapeutics Inc is an advanced biotherapy company focused on the development and commercialization of medications to improve patient health. The company was founded in 2017 by five experienced pharmaceutical experts: Andrew Cheng, Timothy Lu, David D. Kirn, Scott Freeman, and Stuart Lockhart. Akero Therapeutics Inc is headquartered in Belmont, California, USA. The business model of Akero Therapeutics Inc is based on targeted biological therapy aiming to address unmet medical needs in various disease areas. The idea is to reduce the risk of diseases such as diabetes, chronic liver diseases, and metabolic disorders and improve the quality of life for patients through the development of innovative biological agents. Akero Therapeutics is dedicated to combating these diseases with groundbreaking therapeutic approaches. The company offers various divisions including product development, research and development, and commercial. Product development at Akero Therapeutics encompasses the discovery, development, clinical testing, and efficacy assessment of new biological agents. The research division continuously works on identifying new target molecules to develop innovative approaches in disease therapy. The commercial division of Akero Therapeutics is responsible for developing an appropriate marketing strategy to bring the biological agents to market readiness and to patients. One of the most well-known products of Akero Therapeutics is the medication Efruxifermin (EFX). It is a protein molecule developed for the treatment of patients with non-alcoholic fatty liver disease (NAFLD). NAFLD is a disease characterized by the accumulation of fat in the liver without the patient consuming alcohol during the day. Fatty liver disease is a growing public health issue and one of the most common liver diseases worldwide. Akero Therapeutics has developed an effective medication, EFX, which effectively reduces liver fat content. Another product currently in the clinical research phase at Akero Therapeutics is AKR-001. It is a medication for the treatment of patients with lipid metabolism disorders, including hypertriglyceridemia and homozygous familial hypercholesterolemia. Lipid metabolism disorders are characterized by high levels of triglycerides and cholesterol in the blood and increase a patient's risk for cardiovascular diseases. In summary, Akero Therapeutics is a clinical biotherapy company dedicated to the development of treatments for various chronic diseases. The company combines innovative research with strong entrepreneurial capabilities to explore, develop, and bring new biological agents to the market for disease therapy. Akero Therapeutics is on track to establish a strong presence in the biopharmaceutical industry and has the potential to improve the lives of millions of patients worldwide. Akero Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.